专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2006091780A3 NANOPARTICULATE FORMULATIONS OF DOCETAXEL AND ANALOGUES THEREOF 审中-公开
公开(公告)号：WO2006091780A3
公开(公告)日：2006-08-31
申请号：PCT/US2006/006535
申请日：2006-02-24
申请人： ELAN PHARMA INTERNATIONAL LIMITED , LIVERSIDGE, Gary , JENKINS, Scott , LIVERSIDGE, Elaine
发明人： LIVERSIDGE, Gary , JENKINS, Scott , LIVERSIDGE, Elaine
IPC分类号： A61K9/50
摘要： Described are nanoparticulate docetaxel or analogue thereof compositions. The compositions, which comprise a nanoparticulate docetaxel or analogue thereof and at least one surface stabilizer, can be used in the treatment of cancer.

12. 发明申请

WO2006076533A1 CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ACYLANILIDE 审中-公开
标题翻译：控制释放包含ACYLANILIDE的组合物
公开(公告)号：WO2006076533A1
公开(公告)日：2006-07-20
申请号：PCT/US2006/001163
申请日：2006-01-12
申请人： ELAN PHARMA INTERNATIONAL LIMITED , LIVERSIDGE, Gary , JENKINS, Scott
发明人： LIVERSIDGE, Gary , JENKINS, Scott
IPC分类号： A61K9/14 , A61K9/20 , A61K9/26
CPC分类号： A61K9/5084
摘要： The invention relates to a controlled release composition comprising acylanilide, and preferably bicalutamide, for use, in particular, in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analogue for the treatment of stage D2 metastatic carcinoma of the prostate. The controlled release composition comprises an immediate release component and a modified release component or formulation. The immediate release component comprises a first population of bicalutamide. The modified release formulation preferably comprises a second population of acylanilide bicalutamide, and a controlled release constituent. The controlled release formulation is preferably in the form of an erodable formulation, a diffusion controlled formulation or an osmotic controlled formulation. The combination of the immediate release and modified release components in operation deliver the active ingredient in a pulsed or bi-modal manner.
摘要翻译：本发明涉及包含酰基苯胺，优选比卡鲁胺的控释组合物，特别是用于与促黄体生成激素释放激素（LHRH）类似物联合治疗以治疗前列腺D2期转移性癌。控释组合物包含立即释放组分和改性释放组分或制剂。立即释放组分包含比卡鲁胺的第一群体。改性释放制剂优选包含第二种酰基苯胺比卡鲁酰胺和控释组分。控制释放制剂优选为可侵蚀制剂，扩散控制制剂或渗透控制制剂的形式。在操作中即时释放和释放组分的组合以脉冲或双向方式递送活性成分。

13. 发明申请

WO2009152192A1 COMBINATION OF A TRIPTAN AND AN NSAID 审中-公开
标题翻译： TRIPTAN和NSAID的组合
公开(公告)号：WO2009152192A1
公开(公告)日：2009-12-17
申请号：PCT/US2009/046808
申请日：2009-06-10
申请人： ELAN PHARMA INTERNATIONAL LIMITED , JENKINS, Scott , LIVERSIDGE, Gary
发明人： JENKINS, Scott , LIVERSIDGE, Gary
IPC分类号： A61K31/405
CPC分类号： A61K9/5084 , A61K9/146 , A61K9/1676 , A61K9/5078 , A61K31/4045 , A61K31/616 , A61K45/06 , A61K2300/00
摘要： A composition of a triptan and particles of a NSAID. The NSAID particles having an effective average particle size of less than 2000 nm and at least one surface stabilizer adsorbed on the surface thereof. The NSAID component of the composition, in a comparative pharmacokinetic testing with a non-particulate NSAID in the same dosage strength and form, exhibits a shorter time to Tmax when compared to the time to Tmax of the non- nanoparticulate NSAID.
摘要翻译：曲坦类和NSAID颗粒的组合物。具有小于2000nm的有效平均粒径的NSAID颗粒和吸附在其表面上的至少一种表面稳定剂。在与非纳米颗粒NSAID的Tmax时间相比，在具有相同剂量强度和形式的非颗粒NSAID的比较药代动力学测试中，组合物的NSAID组分显示出比Tmax更短的时间。

14. 发明申请

WO2009076620A1 NANOPARTICULATE ANIDULAFUNGIN COMPOSITIONS AND METHODS FOR MAKING THE SAME 审中-公开
标题翻译：纳米抗菌肽组合物及其制备方法
公开(公告)号：WO2009076620A1
公开(公告)日：2009-06-18
申请号：PCT/US2008/086642
申请日：2008-12-12
申请人： ELAN PHARMA INTERNATIONAL LIMITED , JENKINS, Scott , LIVERSIDGE, Gary , NEVILLE, Debbie
发明人： JENKINS, Scott , LIVERSIDGE, Gary , NEVILLE, Debbie
IPC分类号： A01N25/34 , A61K38/00
CPC分类号： A61K38/12 , A61K9/0019 , A61K9/146
摘要： Nanoparticulate compositions comprising anidulaf ungin are described, as well as methods of making such compositions. Also described are methods for treatment of fungal infections.
摘要翻译：描述了包含anginula ungin的纳米颗粒组合物，以及制备这种组合物的方法。还描述了用于治疗真菌感染的方法。

15. 发明申请

WO2008073068A1 NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING CEFDITOREN 审中-公开
标题翻译：包含CEFDITOREN的纳米颗粒和受控释放组合物
公开(公告)号：WO2008073068A1
公开(公告)日：2008-06-19
申请号：PCT/US2006/022117
申请日：2006-06-07
申请人： ELAN PHARMA INTERNATIONAL LIMITED , DEVANE, John , STARK, Paul , FANNING, Niall , REKHI, Gurvinder , JENKINS, Scott , LIVERSIDGE, Gary
发明人： DEVANE, John , STARK, Paul , FANNING, Niall , REKHI, Gurvinder , JENKINS, Scott , LIVERSIDGE, Gary
IPC分类号： A61K9/64
CPC分类号： A61K9/2054 , A61K9/145 , A61K9/146 , A61K9/1676 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/5026 , A61K9/5078 , A61K9/5084 , A61K31/546
摘要： The present invention provides a composition comprising a cefditoren, or a salt, derivative, prodrug, or other form thereof, for example, cefditoren pivoxil, useful in the treatment and prevention of infections and related conditions. The invention provides a composition which comprises nanoparticulate particles comprising the cefditoren, or a salt, derivative, prodrug, or other form thereof and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. The invention provides also a composition that delivers a cefditoren, or a salt, derivative, prodrug, or other form thereof, or nanoparticles comprising the same, in a pulsatile or continuous manner.
摘要翻译：本发明提供一种组合物，其包含可用于治疗和预防感染和相关病症的头孢托仑或其盐，衍生物，前药或其他形式，例如匹戊头孢托仑。本发明提供一种组合物，其包含包含头孢托仑或其盐，衍生物，前药或其它形式的纳米颗粒颗粒和至少一种表面稳定剂。纳米颗粒具有小于约2000nm的有效平均粒度。本发明还提供以脉动或连续方式递送头孢托仑或其盐衍生物，前药或其它形式或包含其的纳米颗粒的组合物。

16. 发明申请

WO2007070082A1 NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING TEPRENONE 审中-公开
标题翻译：含有TEPRENONE的纳米颗粒和受控释放组合物
公开(公告)号：WO2007070082A1
公开(公告)日：2007-06-21
申请号：PCT/US2006/018000
申请日：2006-05-09
申请人： ELAN PHARMA INTERNATIONAL LIMITED , DEVANE, John , STARK, Paul , FANNING, Niall , REKHI, Gurvinder , JENKINS, Scott , LIVERSIDGE, Gary
发明人： DEVANE, John , STARK, Paul , FANNING, Niall , REKHI, Gurvinder , JENKINS, Scott , LIVERSIDGE, Gary
IPC分类号： A61K9/64
CPC分类号： A61K9/2077 , A61K9/1676 , A61K9/2013 , A61K9/5026 , A61K9/5084
摘要： The present invention is directed to compositions comprising a nanoparticulate teprenone having improved bioavailability. The nanoparticulate teprenone particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the prevention and treatment of gastritis and gastric ulcers. The invention also relates to a controlled release composition comprising a teprenone or a nanoparticulate teprenone that in operation delivers the drug in a pulsed or multi-modal manner for the prevention and treatment of gastritis and gastric ulcers.
摘要翻译：本发明涉及包含具有改善的生物利用度的纳米颗粒替泼瑞酮的组合物。组合物的纳米颗粒替普瑞酮颗粒具有小于约2000nm的有效平均粒度，并且可用于预防和治疗胃炎和胃溃疡。本发明还涉及一种控释组合物，其包含替普瑞酮或纳米颗粒替泼瑞酮，其在操作中以脉冲或多模式递送药物以预防和治疗胃炎和胃溃疡。

17. 发明申请

WO2006113310A3 NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING PROSTAGLANDIN DERIVATIVES 审中-公开
公开(公告)号：WO2006113310A3
公开(公告)日：2006-10-26
申请号：PCT/US2006/013784
申请日：2006-04-13
申请人： ELAN PHARMA INTERNATIONAL LIMITED , JENKINS, Scott , LIVERSIDGE, Gary
发明人： JENKINS, Scott , LIVERSIDGE, Gary
IPC分类号： A61K9/14 , A61K9/16 , A61K9/48 , A61K9/50
摘要： The present invention is directed to compositions comprising a nanoparticulate prostaglandin derivative, preferably limaprost or a salt or derivative thereof, having improved bioavailability. The nanoparticulate prostaglandin derivative particles of the composition have an effective average particles size of less than about 2000 nm and are useful in the treatment of ischemic symptoms. The invention also relates to a controlled release composition comprising a prostaglandin derivative, such as limaprost alfadex, or a nanoparticulate prostaglandin derivative, such as limaprost or a salt or derivative thereof, that in operation delivers the drug in a pulsed or bimodal manner for the treatment of ischemic symptoms.

18. 发明申请

WO2006110807A1 CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION 审中-公开
标题翻译：包含CEPHOROSPORIN治疗细菌感染的受控释放组合物
公开(公告)号：WO2006110807A1
公开(公告)日：2006-10-19
申请号：PCT/US2006/013637
申请日：2006-04-12
申请人： ELAN PHARMA INTERNATIONAL LIMITED , JENKINS, Scott , LIVERSIDGE, Gary
发明人： JENKINS, Scott , LIVERSIDGE, Gary
IPC分类号： A61K9/26
CPC分类号： A61K9/5084 , A61K9/1676 , A61K9/5026 , A61K9/5078
摘要： The invention relates to a controlled release composition comprising a cephalosporin that in operation delivers the drug in a pulsed or bimodal manner for the treatment of bacterial infection. The controlled release composition comprises an immediate release component and a modified release component; the immediate release component comprising a first population of cephalosporin-containing particles and the modified release component comprising a second population of cephalosporin-containing particles coated with a controlled release coating; wherein the combination of the immediate release and modified release components in operation deliver the active ingredient in a pulsed or bi-modal manner. Preferably, the cephalosporin is cefcapene pivoxil or a salt thereof which can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile.
摘要翻译：本发明涉及包含头孢菌素的控释组合物，其在操作中以脉冲或双峰方式递送药物用于治疗细菌感染。控释组合物包含立即释放组分和改性释放组分; 所述立即释放组分包含含有头孢菌素的颗粒的第一群体，并且所述改性释放组分包含涂覆有控释层的第二群含头孢菌素的颗粒; 其中操作中的立即释放组分和修饰释放组分的组合以脉冲或双向方式递送活性成分。优选地，头孢菌素是头孢烯酮匹托酯或其盐，其可以以可侵蚀，扩散和/或渗透控制释放曲线从剂型释放。

19. 发明申请

WO2006110800A1 MODIFIED RELEASE COMPOSITIONS COMPRISING A FLUOROCYTIDINE DERIVATIVE FOR THE TREATMENT OF CANCER 审中-公开
标题翻译：包含用于治疗癌症的氟代衍生物的修饰释放组合物
公开(公告)号：WO2006110800A1
公开(公告)日：2006-10-19
申请号：PCT/US2006/013629
申请日：2006-04-12
申请人： ELAN PHARMA INTERNATIONAL LIMITED , JENKINS, Scott , LIVERSIDGE, Gary
发明人： JENKINS, Scott , LIVERSIDGE, Gary
IPC分类号： A61K9/14 , A61K9/48
CPC分类号： A61K9/5078 , A61K31/7068
摘要： The invention relates to a multiparticulate modified release composition comprising a fluorocytidine derivative, preferably capecitabine, and a modified release component comprising a modified release coating, a modified release matrix material, or both. Following oral delivery, the composition in operation delivers the fluorocytidine derivative in a pulsatile manner at about six to about twelve hours after administration.
摘要翻译：本发明涉及包含氟胞嘧啶衍生物，优选卡培他滨的多微粒改性释放组合物和包含改性释放包衣，改性释放基质材料或两者的改性释放组分。口服给药后，给药组合物在施用后约6至约12小时以脉动方式递送氟胞嘧啶衍生物。

20. 发明申请

WO2006088894A2 AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE 审中-公开
标题翻译：纳米颗粒苯并咪唑的喷雾剂和注射剂配方
公开(公告)号：WO2006088894A2
公开(公告)日：2006-08-24
申请号：PCT/US2006/005224
申请日：2006-02-15
申请人： ELAN PHARMA INTERNATIONAL LIMITED , LIVERSIDGE, Gary , JENKINS, Scott
发明人： LIVERSIDGE, Gary , JENKINS, Scott
CPC分类号： A61K31/5513 , A61K9/0019 , A61K9/0043 , A61K9/0073 , A61K9/145 , A61K9/146
摘要： Described are nanoparticulate formulations of a benzodiazepine, such as lorazepam, that does not require the presence of polyethylene glycol and propylene glycol as stabilizers, and methods of making and using such formulations. The formulations are particularly useful in aerosol and injectable dosage forms, and comprise nanoparticulate benzodiazepine, such as lorazepam, and at least one surface stabilizer. The formulations are useful in the treatment of status epilepticus, treatment of irritable bowel syndrome, sleep induction, acute psychosis, and as a pre-anesthesia medication.
摘要翻译：描述的是不需要存在聚乙二醇和丙二醇作为稳定剂的苯并二氮杂，例如劳拉西泮的纳米颗粒制剂，以及制备和使用这些制剂的方法。制剂特别可用于气雾剂和可注射剂型，并且包含纳米颗粒苯二氮卓类，例如劳拉西泮和至少一种表面稳定剂。该制剂可用于治疗癫痫持续状态，治疗肠易激综合征，睡眠诱导，急性精神病以及作为麻醉前药物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式